Atrial fibrillation treatment: present state and future directions

doi:10.3969/j.issn.1004-583X.2016.01.002

Abstract

Abstract: Atrial fibrillation (AF) is an emerging epidemic of cardiovascular disease in the 21st century, and the disease burden is worsening. Warfarin is used for stroke prevention in AF as an effective drug, but its use in patients with AF of our country is still inadequate. With the continuous increase of new oral anticoagulants and left atrial appendage closure technology applications, antithrombotic treatment of AF is facing more choices. Catheter ablation has become the first-line treatment for paroxysmal AF. However,the best strategy for ablation persistent AF is still controversial. In recent years, more and more focuses have been put on life style intervention in the prevention and treatment of AF. The management of AF will expect a new stage in the future.

Key words: atrial fibrillation, anticoagulants, catheter ablation

CLC Number:

R541.75

Guo Xueyuan, Ma Changsheng. Atrial fibrillation treatment: present state and future directions[J]. Clinical Focus, 2016, 31(1): 7-9.

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2016.01.002

https://huicui.hebmu.edu.cn/EN/Y2016/V31/I1/7

References

[1] Chugh SS, Havmoeller R, Narayanan K,et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study[J]. Circulation, 2014,129(8):837-847.
[2] Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060[J]. Eur Heart J, 2013,34(35):2746-2751.
[3] Wong CX, Brooks AG, Leong DP, et al. The increasing burden of atrial fibrillation compared with heart failure and myocardial infarction: a 15-year study of all hospitalizations in Australia[J]. Arch Intern Med, 2012,172(9):739-741.
[4] Shroff GR, Solid CA, Herzog CA, et al. Temporal trends in ischemic stroke and anticoagulation therapy among Medicare patients with atrial fibrillation: a 15-year perspective (1992-2007)[J]. JAMA Intern Med, 2013,173(2):159-160.
[5] 周自强,胡大一. 中国心房颤动现状的流行病学研究[J]. 中华内科杂志,2004,43(7):491-494.
[6] O'Brien EC, Kim S, Hess PL,et al. Effect of the 2014 atrial fibrillation guideline revisions on the proportion of patients recommended for oral anticoagulation[J]. JAMA Intern Med, 2015,175(5):848-850.
[7] Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry[J]. Europace, 2014,16(3):308-319.
[8] Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial[J]. JAMA, 2014,312(19):1988-1998.
[9] Verma A, Jiang CY, Betts TR, et al. Approaches to catheter ablation for persistent atrial fibrillation[J]. N Engl J Med, 2015,372(19):1812-1822.
[10] Dong JZ, Sang CH, Yu RH,et al. Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation[J]. Europace, 2015, May 8.[Epub ahead of print]
[11] Marrouche N, Wilber D, Hindricks G,et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study[J]. JAMA, 2014,311(5):498-506.
[12] Abed HS, Wittert GA, Leong DP,et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial[J]. JAMA, 2013,310(19):2050-2060.
[13] Pathak RK, Middeldorp ME, Lau DH,et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study[J]. J Am Coll Cardio,2014,64(21):2222-2231.

[1]	Wang Yihan, Qin Xuyan, Han Xuanze, Wang Yingjie, Gao Feifei, Chen Chunhong, Zhang Lingnan, Zhang Fang. Efficacy and safety of rivaroxaban therapy in elderly patients with non-valvular atrial fibrillation who had a HASBLED score≥3 [J]. Clinical Focus, 2024, 39(2): 121-124.
[2]	Wang Zhen, Yang Xiaoyue, Li Shaojie, Wang Xian, Chen Shuxia, Gu Jian. Analysis of clinical characteristics and readmission risk factors in patients with ejection fraction preserved heart failure combined with atrial fibrillation [J]. Clinical Focus, 2023, 38(4): 308-314.
[3]	Zhang Fang, Zhang Yichao, Jia Xinwei, Li Jianlong, Chen Chunhong. Analysis of one-year follow-up results of ≥75-year-old atrial fibrillation inpatients with high CHA2DS2-VASc score [J]. Clinical Focus, 2023, 38(2): 117-120.
[4]	Ma Jinghong, Yang Qian, Jia Yongjian, Dang Yi. Risks of cardiac tamponade resulting from uninterrupted novel oral anticoagulants and uninterrupted warfarin during perioperative period of catheter ablation of atrial fibrillation: A meta-analysis [J]. Clinical Focus, 2022, 37(9): 773-778.
[5]	Zhang Haifu, Ye Xiangqing, Chen Zhexu, Chen Shijian, Yang Dong, Zhang Xingwei. Effects of moderate exercise on the prognosis of patients with atrial fibrillation:A systematic review and Meta-analysis [J]. Clinical Focus, 2022, 37(6): 485-489.
[6]	Zhang Jingshui, Xu Yanan, Wang Jun, Yang Yi, Jiang Haibing, Tang Long, Wang Xianping, Shao Mingliang. Clinical characteristics and long-term prognosis of initial patients with new onset different type of heart failure combined atrial fibrillation [J]. Clinical Focus, 2022, 37(6): 504-509.
[7]	Li Heng, Li Yonghui, Sun Xiaoqiang, Wang Lin, He Feng. Efficacy and safety of anticoagulant therapy for patients with heart failure in sinus rhythm [J]. Clinical Focus, 2022, 37(5): 406-411.
[8]	Li Weiwei, Li Yanan. Left atrial volume index predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis [J]. Clinical Focus, 2022, 37(11): 965-968.
[9]	An Jingjing, Wang Xiaojuan, Deng Aiyun. Radiofrequency ablation in treating pre-excited atrial fibrillation recurrence: A meta analysis [J]. Clinical Focus, 2022, 37(10): 899-904.
[10]	Zhao Meili, Xiao Liyuan, Liu Lin, Kang Chao, Zhang Qiuxiang. Correlation between NT-proBNP, hs-CRP, left atrium diameter and chronic heart failure concurrent with atrial fibrillation [J]. Clinical Focus, 2021, 36(5): 412-415.
[11]	Geng Yanping, Wang Lili, Gu Jian, Qi Peng, Chen Shuxia. Validity and reliability analysis of Chinese version of AntiClot Treatment Scale [J]. Clinical Focus, 2020, 35(9): 788-791.
[12]	Ma Jincai, Ma Rongzhi, Ma Zhenzhen. Efficacy and safety of rivaroxaban in elderly patients with nonvalvular atrial fibrillation complicated with cardiac insufficiency [J]. Clinical Focus, 2020, 35(5): 413-416.
[13]	Yang Hua, Meng Limin, Xin Shuanli, Chang Chao, Zhao Xiufeng, Wang Min. Correlation between serum chemerin levels and degree of atrial fibrosis in patients with atrial fibrillation [J]. Clinical Focus, 2020, 35(3): 206-210.
[14]	Lu Yuqin, Li Yingdong, Liu Kai. Role of serum MMP-1, MMP-3, TIMP-1 and Hcy levels in patients with hypertension complicated with atrial fibrillation [J]. Clinical Focus, 2020, 35(11): 976-979.
[15]	Gao Xiuxina, Si Yueqiaoa, Ding Zhenjianga, Zhang Yinga, Liu Huilinga, Liu Jingyia, Han Chaoa, Sunwang Lexianaa. Correlation of platelet distribution width and red blood cell distribution width in peripheral blood with atrial fibrillation in patients with coronary artery disease [J]. Clinical Focus, 2020, 35(11): 984-987.